Navigation Links
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Date:7/30/2008

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced new data showing that its investigational drug Dimebon continues to produce broad, clinically meaningful benefits in Alzheimer's disease patients after long-term dosing, and appears to operate through a novel mechanism of action. These data were presented today in a podium session and two poster sessions at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago. The presentations are highlighted below.

Dimebon Preserves All Key Functions in Alzheimer's Patients for 18 Months in Open-Label Extension of First Pivotal Trial

New data from a six-month open-label extension of the 12-month placebo-controlled study of Dimebon in patients with mild-to-moderate Alzheimer's disease demonstrated that Dimebon continued to improve the clinical course of the disease. After 18 months of treatment, Dimebon preserved function in patients at their original levels upon entering the trial across all key aspects of Alzheimer's disease, specifically memory and thinking, behavior, activities of daily living and overall function. These results are noteworthy as untreated Alzheimer's patients progressively deteriorate over time in these areas. Dimebon remained well tolerated throughout the 18-month treatment period.

The open-label extension data were presented in a poster session by Jeffrey Cummings, M.D., Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA. "To my knowledge, no other approved or investigational treatment has stabilized function across all facets of Alzheimer's disease for this length of time," said Dr. Cummings. "These data suggest that Dimebon may provide long
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
2. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
3. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
4. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
6. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
7. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
8. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...LAND, Calif., Nov. 6 Kaiser Founda...s (KFHP/H), and their subsidiaries reported today ...n for the quarter ended September 30, 2009, compar...ear. Operating income in the third quarter was $33...uarter of last year. Net non-operating income was ...
(Date:11/6/2009)...ROIT, Nov. 6 Caraco Phar...as launched ketorolac tromethamine ophthalmic solu...Food and Drug Administration (FDA) for Sun Pharma,...ric Acular® ophthalmic solution on the first ...ketorolac is therapeutically equivalent to Acular&...
(Date:11/6/2009)...NCETON, N.J., Nov. 6 D...a provider of advanced wound care products, announ...s before market on Monday, November 16, 2009. The ...to discuss the results at 11:00 am EST. Interested...(857) 350-1684 (international), with passcode 8141...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2AstraZeneca Submits New Drug Applications for ZACTIMA 28TM 29 in Second Line Advanced Non Small Cell Lung Cancer 53204 1AstraZeneca Submits New Drug Applications for ZACTIMA 28TM 29 in Second Line Advanced Non Small Cell Lung Cancer 53204 2AstraZeneca Submits New Drug Applications for ZACTIMA 28TM 29 in Second Line Advanced Non Small Cell Lung Cancer 53204 3AstraZeneca Submits New Drug Applications for ZACTIMA 28TM 29 in Second Line Advanced Non Small Cell Lung Cancer 53204 4Sunesis Receives Approval for Listing on The NASDAQ Capital Market 13280 1Sunesis Receives Approval for Listing on The NASDAQ Capital Market 13280 2Sunesis Receives Approval for Listing on The NASDAQ Capital Market 13280 3Lotus Pharmaceuticals Inc Announces Patent Pending Gliclazide Controlled Release Tablets 13278 1Lotus Pharmaceuticals Inc Announces Patent Pending Gliclazide Controlled Release Tablets 13278 2Lotus Pharmaceuticals Inc Announces Patent Pending Gliclazide Controlled Release Tablets 13278 3
(Date:11/9/2009)..., MAYWOOD, Il. -- Gifted young athletes are und... round. , But a new Loyola University Health Sys...hat such specialization increases the risk of inju...ed States Tennis Association junior competition fo...re more likely to withdraw from tournaments for me...
(Date:11/8/2009)..., WASHINGTON, Nov. 8 ...ssued the following statement about the passage of...s and the American voters a lot about core values....core values, seeking to overcome the struggles ord...gles mean that many cannot afford basic healthcare...
(Date:11/8/2009)...traight-back, chest-out position promotes self-ass...8 (HealthDay News) -- Your mother may have been ri...arch suggests that good posture could make you fee...of us were taught that sitting up straight gives a...co-author of the study and a psychology professor ...
(Date:11/8/2009)..., WASHINGTON, Nov. 8 ...a press conference following the House passage of ...Act. The bill passed by a vote of 220 to 215. Be...nd some of my colleagues just received a call from... congratulating us on a great victory for the Amer...
(Date:11/8/2009)... Freeze-drying of biopharm...Mississauga, Ontario facility. , ...homas Wellner, President and CEO of Therapure Biop...ken delivery of a commercial scale pharmaceutical ...scale freeze drying (lyophilization) available for...
Breaking Medicine News(10 mins):Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
...ally common after the death of a spouse , ... keep up active social lives as they age may be do...ng socially active may increase feelings of self-w...llenges, keeping the brain more agile. , "We asses...
...sing Home Care Slashed,$3.7 Million in Year Ahead;...o Publicly Oppose Cuts to Seniors, Medicare Fundin...ck in Minnesota this week for the Memorial Day dis...nistration,s,planned regulatory cuts to seniors, M...
... not like,re-engineering -- they focus on incremen...hese increments can grow to be quite large --,comp...n savings of $1.2,million from their largest-impac...www3.best-in-class.com/dr308.htm ., Quality leade...
...ance to Workers, ERIE, Pa., May 29 Governor Edwa...d adults in Erie County -- many of whom,who work f...a waiting list,to receive health care coverage -- ...ce would also,benefit from the plan,s $42 million ...
...dvanced fibrosis have twice the risk of developing...ndings are published in the June issue of Hepatolo...half of the American Association for the Study of ...hat diabetes increases ones risk for hepatocellula...
...s -, MISSISSAUGA, ON, May 29 /PRNewswire-FirstCal...g development company focused on the research and,...ugh the skin using its,topical and transdermal dru...vel topical pain formulation with the,potential to...
Other Medicine News:Health News:Active Social Life Helps Keep Aging Mind Sharp 2Health News:Active Social Life Helps Keep Aging Mind Sharp 3Health News:Minnesota, National Long Term Care Advocates: Pending Bush Medicare Cut Hurts State's Rural Seniors 2Health News:Minnesota, National Long Term Care Advocates: Pending Bush Medicare Cut Hurts State's Rural Seniors 3Health News:Minnesota, National Long Term Care Advocates: Pending Bush Medicare Cut Hurts State's Rural Seniors 4Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 3Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 4Health News:Diabetes doubles liver cancer risk for patients with advanced hepatitis C 2Health News:Nuvo licenses topical pain product from Paladin 2Health News:Nuvo licenses topical pain product from Paladin 3
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: